ATOSSA THERAPEUTICS INC (ATOS) Fundamental Analysis & Valuation

NASDAQ:ATOS • US04962H7044

Current stock price

5.33 USD
-0.04 (-0.74%)
At close:
5.0868 USD
-0.24 (-4.56%)
After Hours:

This ATOS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATOS Profitability Analysis

1.1 Basic Checks

  • In the past year ATOS has reported negative net income.
  • In the past year ATOS has reported a negative cash flow from operations.
  • In the past 5 years ATOS always reported negative net income.
  • ATOS had a negative operating cash flow in each of the past 5 years.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of ATOS (-73.03%) is worse than 65.83% of its industry peers.
  • ATOS's Return On Equity of -88.35% is in line compared to the rest of the industry. ATOS outperforms 46.41% of its industry peers.
Industry RankSector Rank
ROA -73.03%
ROE -88.35%
ROIC N/A
ROA(3y)-45.89%
ROA(5y)-34.82%
ROE(3y)-52.37%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ATOS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ATOS has about the same amount of shares outstanding.
  • The number of shares outstanding for ATOS has been increased compared to 5 years ago.
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • ATOS has an Altman-Z score of -5.52. This is a bad value and indicates that ATOS is not financially healthy and even has some risk of bankruptcy.
  • ATOS's Altman-Z score of -5.52 is on the low side compared to the rest of the industry. ATOS is outperformed by 65.63% of its industry peers.
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.52
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.53 indicates that ATOS has no problem at all paying its short term obligations.
  • ATOS has a Current ratio of 5.53. This is comparable to the rest of the industry: ATOS outperforms 58.45% of its industry peers.
  • A Quick Ratio of 5.53 indicates that ATOS has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.53, ATOS perfoms like the industry average, outperforming 59.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.53
Quick Ratio 5.53
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ATOS Growth Analysis

3.1 Past

  • ATOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.25%.
EPS 1Y (TTM)-88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ATOS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.57% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.49%
EPS Next 2Y23.01%
EPS Next 3Y13.6%
EPS Next 5Y14.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2028 2029 2030 2031 2032 2033 200M 400M 600M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATOS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATOS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ATOS's earnings are expected to grow with 13.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.01%
EPS Next 3Y13.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATOS Dividend Analysis

5.1 Amount

  • No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATOS Fundamentals: All Metrics, Ratios and Statistics

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (5/1/2026, 8:10:26 PM)

After market: 5.0868 -0.24 (-4.56%)

5.33

-0.04 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-25
Earnings (Next)05-11
Inst Owners21.45%
Inst Owner Change-100%
Ins Owners0.78%
Ins Owner Change292.62%
Market Cap45.89M
Revenue(TTM)N/A
Net Income(TTM)-34.77M
Analysts82
Price Target44.63 (737.34%)
Short Float %4.15%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.2%
Min EPS beat(2)-165.46%
Max EPS beat(2)-2.94%
EPS beat(4)1
Avg EPS beat(4)-43.56%
Min EPS beat(4)-165.46%
Max EPS beat(4)13.5%
EPS beat(8)4
Avg EPS beat(8)-14.43%
EPS beat(12)6
Avg EPS beat(12)-12.8%
EPS beat(16)10
Avg EPS beat(16)-6.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-36.36%
PT rev (3m)660.87%
EPS NQ rev (1m)-565.58%
EPS NQ rev (3m)-8647.61%
EPS NY rev (1m)-15%
EPS NY rev (3m)-1431.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-5.93
EYN/A
EPS(NY)-4.48
Fwd EYN/A
FCF(TTM)-3.46
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS0
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -73.03%
ROE -88.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.89%
ROA(5y)-34.82%
ROE(3y)-52.37%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 143.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.53
Quick Ratio 5.53
Altman-Z -5.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)105.46%
Cap/Depr(5y)133.28%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-310.67%
EPS Next Y24.49%
EPS Next 2Y23.01%
EPS Next 3Y13.6%
EPS Next 5Y14.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.52%
OCF growth 3YN/A
OCF growth 5YN/A

ATOSSA THERAPEUTICS INC / ATOS Fundamental Analysis FAQ

What is the fundamental rating for ATOS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATOS.


Can you provide the valuation status for ATOSSA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ATOSSA THERAPEUTICS INC (ATOS). This can be considered as Overvalued.


How profitable is ATOSSA THERAPEUTICS INC (ATOS) stock?

ATOSSA THERAPEUTICS INC (ATOS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ATOS stock?

The Earnings per Share (EPS) of ATOSSA THERAPEUTICS INC (ATOS) is expected to grow by 24.49% in the next year.